Jun 1, 2008
By:
Patrick Clinton
An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner
|
Jun 1, 2008
By:
Patrick Clinton
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?
|
May 28, 2008
By:
Patrick Clinton
A new study ranks Pfizer's anti-smoking drug as number one in generating adverse event reports. That's bad news for Pfizer—but in the long run, what does it really mean?
|
Apr 1, 2008
By:
Patrick Clinton
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
|
Apr 1, 2008
By:
Patrick Clinton
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
|
Mar 1, 2008
By:
Patrick Clinton
For pharma to function, it needs a whole network that commands trust. The only alternative is the sort of regulation by mass tort that we've been sliding into in recent years
|
New from Pharm Exec: an awards program for young pharma leaders, a redesigned Web site, a blog, and expanded coverage
Feb 1, 2008
By:
Patrick Clinton
New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders
|
|
Jan 1, 2008
By:
Patrick Clinton
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
|
|
Dec 1, 2007
By:
Patrick Clinton
For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
